A study to assess whether a product call relacorilant works and is safe to use in patients with Cushing Syndrome; some patients will receive relacorilant whilst others receive a placebo.
- Conditions
- Endogenous Cushing syndromeMedDRA version: 20.0 Level: LLT Classification code 10011657 Term: Cushings syndrome System Organ Class: 100000004860Therapeutic area: Body processes [G] - Physiological processes [G07]
- Registration Number
- EUCTR2018-003096-35-ES
- Lead Sponsor
- Corcept Therapeutics Incorporated
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Not specified
- Target Recruitment
- 130
To enroll in the study, each patient must meet the following key inclusion criteria:
1. Male or female, 18 to 80 years of age, inclusive
2. Has a confirmed biochemical diagnosis of endogenous Cushing syndrome based on the presence of at least 2 of the following:
• UFC above the upper limit of normal (ULN) (50.0 µg/24 hours) in at least 2 complete 24-hour tests within 3 weeks prior to Baseline
• Late-night salivary cortisol >ULN in at least 2 tests (using a salivette) within 3 weeks prior to Baseline
• Lack of cortisol suppression (>1.8 µg/dL serum cortisol) on either 1-mg overnight or 2-mg 48-hour dexamethasone suppression testing during Screening, or within 12 weeks before signing the informed consent
3. Has at least 2 of the following clinical signs and symptoms of Cushing syndrome:
• Bodily characteristics of a Cushingoid appearance (e.g., facial rubor, moon facies, dorsocervical fat pad, supraclavicular fat pad)
• Increased body weight or central obesity
• Proximal muscle weakness
• Low bone mass based on DXA scan
• Psychiatric symptoms (including depression or psychosis)
• Skin manifestations: violaceous striae, acne, and/or hirsutism
• Easy bruisability
4. Has at least 1 of the following at Baseline:
• DM (fasting plasma glucose =126 mg/dL and/or 2-hour oGTT plasma glucose =200 mg/dL at 2 hours), or IGT (plasma glucose =140 mg/dL and <200 mg/dL on a 2-hour oGTT) glucose
• Uncontrolled hypertension (mean SBP =135 to =170 mm Hg and/or mean DBP =85 to =110 mm Hg) based on 24-hour ABPM
5. If receiving medical treatment for DM/IGT or hypertension, is on a stable dose of medication for at least 4 weeks prior to Baseline
6. If receiving medical treatment for depression, is on a stable dose of medication for at least 6 weeks prior to Baseline
7. If female, has a negative serum pregnancy test at Screening and negative urine pregnancy test at Baseline
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 117
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 13
Patients who meet any of the following criteria will not be permitted entry to the study:
1. Has severe, uncontrolled hypertension (mean SBP >170 mm Hg or mean DBP >110 mg at Screening), based on 24-hour ABPM
2. Has poorly controlled DM (HbA1c >12% at Screening)
3. Has abnormal liver test results (total bilirubin >1.5×ULN or elevated alanine aminotransferase or aspartate aminotransferase >3×ULN at Baseline)
4. Has severe renal insufficiency (glomerular filtration rate =29 mL/min at Baseline)
5. Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism
6. Has prolonged QT interval corrected for heart rate using Fridericia’s equation (QTcF) (>450 ms for men and >470 ms for women) with normal QRS interval (<120 ms) or QTcF interval >500 ms with wide QRS interval (=120 ms)
7. Has received pituitary radiation therapy for a Cushing syndrome-related tumor within 1 year of Screening
8. Has used or plans to use any of the following treatments for Cushing syndrome within
4 weeks prior to Baseline:
• Mifepristone
• Adrenostatic medications: metyrapone, ketoconazole, fluconazole, aminoglutethimide, or etomidate
• Serotonin antagonists: cyproheptadine, ketanserin, or ritanserin
• Dopamine agonists: bromocriptine or cabergoline
• Gamma-aminobutyric acid agonists: sodium valproate
• Short-acting somatostatin analogs: octreotide, lanreotide, or pasireotide
9. Has used or plans to use somatostatin receptor ligands: long-acting octreotide or pasireotide within 8 weeks prior to Baseline
10. Has adrenocortical carcinoma
11. Has ectopic Cushing syndrome and a life expectancy of <3 years
12. Has pseudo-Cushing syndrome. Patients with known or suspected pseudo-Cushingsyndrome based on medical history (such as patients with severe obesity, major depression, or a history of alcoholism) should undergo a dexamethasone-CRHDDAVP stimulation test to rule-in or rule-out this possibility
13. Has taken any investigational drug within 4 weeks prior to Baseline, or within less than 5 times the drug’s half-life, whichever is longer
14. Ongoing use of antidiabetic, antihypertensive, antidepressant, or lipid-lowering medications that are highly dependent on CYP3A for clearance and require dose modification upon coadministration with strong CYP3A inhibitors
15. Ongoing use of any strong CYP3A4 inhibitor or any other prohibited medications
16. Is pregnant or lactating
17. Has an acute or unstable medical problem that could be aggravated by treatment with the investigational study drug
18. Has a history of hypersensitivity or severe reaction to the study drug, to a similar class of drug, or to the study drug’s excipient
19. In the Investigator’s opinion, should not participate in the study or may not be capable of following the study schedule
20. Has known HIV or hepatitis B or C infection
21. Is a family member of one of the Sponsor’s employees, the Investigator, or the site staff directly working on the study
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method